R&D Reorg Helps Astellas Move Swiftly With Protein Degraders

In selecting targeted protein degradation as a new Primary Focus area within its R&D effort, Astellas has moved rapidly to develop a potential first-in-class KRAS G12D degrader candidate ASP3082, helped by a reorganization last year to develop a more agile research function. The Japanese firm sees very broad potential for TPDs beyond oncology in the longer term.